Replimune Group

After FDA approval of TujuCare for advanced melanoma, Replimune outlines a cautious, staged launch, initially with 200 first‑user centers and 70% of the commercial team already hired. The list price is $450,000 per patient based on the median use in the IGNYTE study, though early revenue is likely to be dampened by an initially lower dose and training and reimbursement efforts. The company is launching with a temporary J‑code and expects acceleration in Q3–Q4; manufacturing costs are estimated at about 10% of revenue. Replimune is also advancing a broad pipeline, including RP2 for metastatic uveal melanoma (REVEAL study) and the confirmatory IGNYTE‑3 study, which is still recruiting and aimed at readout by 2030. » More on de.investing.com

Replimune Group’s stock rose to a 52-week high of $16.20, well above its yearly low of $1.50. Over the past year the price climbed about 166%, roughly 119% in the last six months and around 61% year-to-date. Analysts consider the stock above its fair value, citing price targets between $14 and $24, and several firms raised their estimates after the accelerated FDA approval of Tudriqev in combination with Nivolumab. » More on de.investing.com

Replimune Group’s stock rose to a 52-week high of $15.72 and is currently trading at $15.69, implying a market capitalization of about $1.47 billion. Over the past year the share gained 174.3%, while InvestingPro warns the stock may currently be trading above its fair value. Options data suggest a potential price move of roughly 5.6% ahead of the quarterly results. Several analysts (Wedbush, Leerink, Cantor Fitzgerald) raised their valuations following the FDA approval of Tudriqev and positive prospects for RP-1 in combination with nivolumab. » More on de.investing.com